Results 141 to 150 of about 28,018 (262)

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen   +4 more
wiley   +1 more source

Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12‐Month Real‐World Results

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the real‐world effectiveness of tirzepatide in commercially insured individuals without diabetes, eligible for obesity medications (OMs), including glucagon like‐peptide‐1 receptor agonist (GLP‐1 RA)‐naïve individuals (i.e., no GLP‐1 RA prescription during the 12‐month pre‐index period) and GLP‐1 RA‐experienced ...
Chanadda Chinthammit, Theresa Hunter Gibble, Melody Dehghan, Donna Mojdami, Ahong Huang, David Schapiro, Harold Bays   +6 more
wiley   +1 more source

GLP‐1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Psychotropic medications are frequently associated with weight gain and metabolic syndrome. While GLP‐1 receptor agonists (GLP‐1RAs) have generated interest for managing these adverse effects, their current uses in psychiatric populations have to be described.
Nathan du Soulier, Julien Bezin, Louise Carton, Sibylle de Germay, Jean‐Luc Faillie, Antoine Pariente   +5 more
wiley   +1 more source

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown.
Gwen Aubrac, Rafeya V. Raquib, Minh T. Le, Michael Webster‐Clark, Robert W. Platt, Andrew C. Stokes   +5 more
wiley   +1 more source

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno, Tyla I. Alexander, William K. Karlsson, Haidar M. Al‐Khazali, Michael L. Garelja, Rune H. Christensen, Messoud Ashina, Debbie L. Hay, Håkan Ashina   +8 more
wiley   +1 more source

Subspecialty headache clinic visit reduced healthcare utilization in patients with migraine: Single institution retrospective cohort study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate whether care in a subspecialty headache center, compared with a general neurology clinic, was associated with lower 90‐day unplanned healthcare utilization (HCU) in patients with migraine and to identify patient‐level factors associated with higher unplanned HCU. Background Migraine is a common, disabling
Megan Trenz, Raja Narendra Divakar Addanki, Jason Raad, Robert Kaniecki, Janel Hanmer, Manisha Jhamb, Wesley T. Kerr, Parthasarathy D. Thirumala   +7 more
wiley   +1 more source

Topiramate Impairs Spermatogenesis, Sperm Parameters, and Epididymal Duct Contractility in Rats. [PDF]

ACS Pharmacol Transl Sci
de Sena MO, da Silva MS, Carvalho YDV, Cunha Chaves HJ, da Costa ML, Figueredo BDS, de Lima JNG, Silva RSE, do Nascimento Junior ES, Rocha AKAA, Gavioli EC, da Silva Junior ED.   +11 more
europepmc   +1 more source

Longitudinal effects of CGRP‐targeting migraine therapies on blood pressure and body mass index: A 12‐month retrospective analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare blood pressure (BP) and body mass index (BMI) trajectories associated with individual calcitonin gene‐related peptide (CGRP)‐targeting migraine therapies versus matched CGRP‐unexposed controls. Background CGRP is a potent vasodilator with established roles in vascular homeostasis and metabolic regulation.
Phillip Phan, Scott Keith, Michael Li, Richard Hass, Wan‐Jen Hsieh, Michael Marmura, Hsiangkuo Yuan   +6 more
wiley   +1 more source

Development and validation of a pharmacokinetic tool to convert random topiramate concentrations to standardized trough levels in bipolar disorder. [PDF]

Front Pharmacol
Jv X, Li S, Liu Y, Cao Q, Li G, Chen M, Liu J, Dong J.   +7 more
europepmc   +1 more source

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source